ArticleFrontiers in neurology2025
A gut microbiota-based predictive model for the treatment efficacy of Parkinson's disease.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop and validate a predictive model for the decline in treatment efficacy among Parkinson's disease (PD) patients based on clinical characteristics and biological markers, providing a basis for early risk identification and personalized therapeutic strategies. Methods: A retrospective study was conducted on 500 PD patients admitted to our hospital between January 2021 and December 2024. The patients were randomly divided into a training set ( Results: No significant differences in baseline characteristics were observed between the training and validation sets (all Conclusion: The RF model incorporating clinical and biological markers effectively predicts decline in treatment efficacy among PD patients, with fecal calprotectin, fecal lactoferrin, and the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.